BackEntrada Therapeutics Overview

Entrada Therapeutics Profit Margin

Latest profit margin for Entrada Therapeutics: -4057.98% — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

Quarterly Profit Margin

-4391.38%
↓ 60.59% YoY

As of Sep 2026

Annual Profit Margin (TTM)

-4057.98%
↓ 2313.10% YoY

Trailing 12 months ending Sep 2026

Average Profit Margin (Comparison Companies)

Loading

Profit Margin History

Loading

Profit Margin Comparison

Loading

Annual Profit Margin Growth Rate (%)

Loading

Entrada Therapeutics (TRDA) FAQ

Entrada Therapeutics (TRDA) currently reports a profit margin of -4057.98% as of September 2026. That compares with -168.16% in the prior-year period — down 2313.1% year over year. That is below the sector sector average of 13.4%. Use the charts on this page to explore Entrada Therapeutics's profit margin history and peer comparisons.

Entrada Therapeutics's profit margin decreased from -168.16% to -4057.98% — a 2313.1% year-over-year decrease (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Entrada Therapeutics's profit margin of -4057.98% is lower than the its sector sector average of 13.4%. That is roughly 30375.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Entrada Therapeutics's current -4057.98% should be judged against industry norms (sector average: 13.4%) and against TRDA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -4057.98%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 13.4%. From there, open related valuation or income-statement pages for Entrada Therapeutics, and consider following TRDA for alerts when major investors trade the stock.